The DOI matches its Crossref record; 104 of the 105 references it cites were found in a registry or an index.
Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches
Open accessAbstract
Progressive supranuclear palsy (PSP), previously believed to be a common cause of atypical parkinsonism, is now recognised as a range of motor and behavioural syndromes that are associated with a characteristic 4-repeat tau neuropathology. New research criteria that recognise early presentations of PSP and operationalise diagnosis of the full spectrum of clinical phenotypes have been reported. The Movement Disorders Society PSP diagnostic criteria include syndromes with few or mild symptoms that are suggestive of underlying PSP pathology and could provide an opportunity for earlier therapeutic interventions in the future. These criteria also include definitions for variant PSP syndromes with different patterns of movement, language, or behavioural features than have been conclusively associated with PSP pathology. Data from new diagnostic biomarkers can be combined with the clinical features of disease to increase the specificity of the new criteria for underlying PSP pathology. Because PSP is associated with tau protein abnormalities, there is growing interest in clinical trials of new tau-directed therapies. These therapies are hypothesised to have disease-modifying effects by reducing the concentration of toxic forms of tau in the brain or by compensating for loss of tau function. Since tau pathology is also central to Alzheimer's disease and chronic traumatic encephalopathy, a successful tau therapeutic for PSP might inform treatment of other neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Although the presence of an overt frontotemporal dementia syndrome can be defined on the basis of established criteria, there are no such criteria for the prodromal forms of fronto temporal lobar degeneration, except for progressive supranuclear See Online for appendix Review palsy.31”
From Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations (2022) · cites this paper as [31]
In the citing paper
“Neuropathologically, PSP is defined by the accumulation of pTau in both neurons and glial cells.369”
From Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023) · cites this paper as [369]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Classification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Appelhof, B., Bakker, C., den IJssel, J. C. L. V. D., Zwijsen, S. A., Smalbrugge, M., Verhey, F. R. J., de Vugt, M. E., Zuidema, S. U., & Koopmans, R. T. C. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477087 · Cited by 2,774
Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538
Self-citationClinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
Höglinger, G. U., Respondek, G., Stamelou, M., Kurz, C., Josephs, K. A., Lang, A. E., Mollenhauer, B., Müller, U., Nilsson, C., Whitwell, J. L., et al. (2017) · Movement Disorders · doi:10.1002/mds.26987 · Cited by 2,434
Self-citationQualitative Assessment of Verbal Fluency Performance in Frontotemporal Dementia
van den Berg, E., Jiskoot, L. C., Grosveld, M. J. H., Swieten, J. C. V., & Papma, J. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477538 · Cited by 2,065
Progressive Supranuclear Palsy
Steele, J. C. (1964) · Archives of Neurology · doi:10.1001/archneur.1964.00460160003001 · Cited by 1,930
Criteria for the diagnosis of corticobasal degeneration
Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., Boxer, A. L., Dickson, D. W., Grossman, M., Hallett, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31827f0fd1 · Cited by 1,904
Self-citationDepletion of microglia and inhibition of exosome synthesis halt tau propagation
Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S., & Ikezu, T. (2015) · Nature Neuroscience · doi:10.1038/nn.4132 · Cited by 1,591
MDS research criteria for prodromal Parkinson's disease
Berg, D., Postuma, R. B., Adler, C. H., Bloem, B. R., Chan, P., Dubois, B., Gasser, T., Goetz, C. G., Halliday, G. M., Joseph, L., et al. (2015) · Movement Disorders · doi:10.1002/mds.26431 · Cited by 1,394
Self-citation
Cited by
Sorted by citations
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
Höglinger, G. U., Respondek, G., Stamelou, M., Kurz, C., Josephs, K. A., Lang, A. E., Mollenhauer, B., Müller, U., Nilsson, C., Whitwell, J. L., et al. (2017) · Movement Disorders · doi:10.1002/mds.26987 · Cited by 2,434
Self-citationMicroglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616
Tauopathies: new perspectives and challenges
Zhang, Y., Wu, K.-M., Yang, L., Dong, Q., & Yu, J.-T. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00533-z · Cited by 323
Self-citationAssessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy
Brendel, M., Barthel, H., van Eimeren, T., MAREK, K. L., Beyer, L., Song, M., Palleis, C., Gehmeyr, M., Fietzek, U. M., Respondek, G., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.2526 · Cited by 267
Self-citationBoeve, B. F., Boxer, A. L., Kumfor, F., Pijnenburg, Y., & Rohrer, J. D. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00341-0 · Cited by 218
Self-citationVaz, R. L., Outeiro, T. F., & Ferreira, J. J. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00347 · Cited by 181
Quattrone, A., Morelli, M., Nigro, S. L., Quattrone, A., Vescio, B., Arabia, G., Nicoletti, G., Nisticò, R., Salsone, M., Novellino, F., et al. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.07.016 · Cited by 160
Höglinger, G. U., Litvan, I., Mendonça, N., Wang, D., Zheng, H., Rendenbach‐Mueller, B., Lon, H., Jin, Z., Fisseha, N., Budur, K. S., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30489-0 · Cited by 150
Self-citationDam, T., Boxer, A. L., Golbe, L. I., Höglinger, G. U., Morris, H. R., Litvan, I., Lang, A. E., Corvol, J., Aiba, I., Grundman, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01455-x · Cited by 152
Self-citationEvolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies
Stamelou, M., Respondek, G., Giagkou, N., Whitwell, J. L., Kovács, G. G., & Höglinger, G. U. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00541-5 · Cited by 149
Self-citationBoxer, A. L., Qureshi, I., Ahlijanian, M. K., Grundman, M., Golbe, L. I., Litvan, I., Honig, L. S., Tuite, P., McFarland, N. R., O’Suilleabhain, P. E., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30139-5 · Cited by 143
Self-citationRoemer, S. F., Grinberg, L. T., Crary, J. F., Seeley, W. W., McKee, A. C., Kovács, G. G., Beach, T. G., Duyckaerts, C. J., Ferrer, I., Gelpí, E., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02479-4 · Cited by 130
Alcolea, D. A., Clarimón, J., Carmona‐Iragui, M., Illán‐Gala, I., Morenas‐Rodríguez, E., Barroeta, I., Nogué, R. R., Sala, I., Sánchez‐Saudinós, M. B., Videla, L., et al. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.09.005 · Cited by 128
Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease
Gaig, C., Compta, Y., Heidbreder, A., Martı́, M. J., Titulaer, M. J., Crijnen, Y. S., Högl, B., Lewerenz, J., Erro, M. E., García‐Moncó, J. C., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012639 · Cited by 120
Self-citationCSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP
Rojas, J. C., Bang, J., Lobach, I. V., Tsai, R. M., Rabinovici, G. D., Miller, B. L., Boxer, A. L., AL-108-231 Investigators, Williams, D. R., Lafontaine, A. L., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004859 · Cited by 113
Self-citationSantangelo, G., Cuoco, S., Pellecchia, M. T., Erro, R., Barone, P., & Picillo, M. (2018) · Journal of Neurology · doi:10.1007/s00415-018-9038-x · Cited by 112
Clinical Utility of 18F‐APN ‐1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy
Li, L., Liu, F., Li, M., Lu, J., Sun, Y., Liang, X., Bao, W., Chen, Q.-S., Li, X., Zhou, X., et al. (2021) · Movement Disorders · doi:10.1002/mds.28672 · Cited by 98
CXCR4 involvement in neurodegenerative diseases
Bonham, L. W., Karch, C. M. M., Fan, C. C., Tan, C. H., Geier, E. G., Wang, Y., Wen, N., Broce, I., Li, Y., Barkovich, M. J., et al. (2018) · Translational Psychiatry · doi:10.1038/s41398-017-0049-7 · Cited by 94
Self-citationSánchez-Contreras, M., Kouri, N., Cook, C. N., Serie, D., Heckman, M. G., Finch, N. A., Caselli, R. J., Uitti, R. J., Wszołek, Z. K., Graff‐Radford, N. R., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0267-3 · Cited by 92
Physiological changes in neurodegeneration—mechanistic insights and clinical utility
Ahmed, R. M., Ke, Y. D., Vucic, S., Ittner, L. M., Seeley, W., Hodges, J. R., Piguet, O., Halliday, G., & Kiernan, M. C. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.23 · Cited by 91
Gait and postural disorders in parkinsonism: a clinical approach
Raccagni, C., Nonnekes, J. H., Bloem, B. R., Peball, M., Boehme, C., Seppi, K., & Wenning, G. K. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09382-1 · Cited by 101
Salivary alpha-synuclein in the diagnosis of Parkinson's disease and Progressive Supranuclear Palsy
Vivacqua, G., Suppa, A., Mancinelli, R., Belvisi, D., Fabbrini, A., Costanzo, M., Formica, A., Onori, P., Fabbrini, G., & Berardelli, A. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.02.014 · Cited by 88
Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies
Silva, M. C., & Haggarty, S. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238948 · Cited by 89
Vos, M. D., Prince, J., Buchanan, T. J., FitzGerald, J. J., & Antoniades, C. A. (2020) · Gait & Posture · doi:10.1016/j.gaitpost.2020.02.007 · Cited by 89
Kynurenic Acid Levels are Increased in the CSF of Alzheimer’s Disease Patients
González-Sánchez, M., Jiménez, J., Narváez, A., Antequera, D., Llamas-Velasco, S., Martín, A. H.-S., Molina Arjona, J. A., López de Munain, A., Lleó Bisa, A., Marco, M.-P., et al. (2020) · Biomolecules · doi:10.3390/biom10040571 · Cited by 84
Bluett, B., Pantelyat, A. Y., Litvan, I., Ali, F., Apetauerova, D., Bega, D., Bloom, L., Bower, J. H., Boxer, A. L., Dale, M. L., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.694872 · Cited by 92
Self-citationThe therapeutic landscape of tauopathies: challenges and prospects
Cummings, J. L., González, M. I., Pritchard, M. C., May, P. C., Toledo, L. M., & Harris, G. A. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01321-7 · Cited by 85
Validation of the Movement Disorder Society Criteria for the Diagnosis of 4‐Repeat Tauopathies
Respondek, G., Grimm, M., Piot, I., Arzberger, T., Compta, Y., Englund, E. M., Ferguson, L. W., Gelpí, E., Roeber, S., Giese, A., et al. (2019) · Movement Disorders · doi:10.1002/mds.27872 · Cited by 79
Self-citationA critical appraisal of tau‐targeting therapies for primary and secondary tauopathies
Imbimbo, B. P., Ippati, S., Watling, M., & Balducci, C. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12453 · Cited by 76
Boxer, A. L., Gold, M., Feldman, H., Boeve, B. F., Dickinson, S. L.-J., Fillit, H., Ho, C., Paul, R., Pearlman, R., Sutherland, M., et al. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.06.4956 · Cited by 71
Self-citationManna, I., Quattrone, A., Benedittis, S. D., Vescio, B., Iaccino, E., & Quattrone, A. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2021.11.020 · Cited by 70
Lebouvier, T., Pasquier, F., & Buée, L. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000502 · Cited by 77
Genetics of Progressive Supranuclear Palsy: A Review
Wen, Y., Zhou, Y., Jiao, B., & Shen, L. H. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202302 · Cited by 64
Characterization of tau binding by gosuranemab
Sopko, R., Golonzhka, O., Arndt, J. W., Quan, C., Czerkowicz, J., Cameron, A., Smith, B., Yogapriya, M., Gibbons, G. S., Kim, S., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105120 · Cited by 65
Talai, A. S., Sedlacik, J., Boelmans, K., & Forkert, N. D. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.648548 · Cited by 64
Clinical Aspects of the Differential Diagnosis of Parkinson’s Disease and Parkinsonism
Shin, H., Hong, S.-W., & Youn, Y. C. (2022) · Journal of Clinical Neurology · doi:10.3988/jcn.2022.18.3.259 · Cited by 72
Heckman, M. G., Brennan, R. R., Labbé, C., Soto, A. I., Koga, S., Deture, M. A., Murray, M. E., Petersen, R. C., Boeve, B. F., van Gerpen, J. A., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.0250 · Cited by 58
New classification of tauopathies
Höglinger, G. U., Respondek, G., & Kovacs, G. G. (2018) · Revue Neurologique · doi:10.1016/j.neurol.2018.07.001 · Cited by 57
Self-citationCapozzo, R., Zoccolella, S., Frisullo, M. E., Barone, R., Dell’Abate, M. T., Barulli, M. R., Musio, M., Accogli, M., & Logroscino, G. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200589 · Cited by 57
MR planimetry in neurodegenerative parkinsonism yields high diagnostic accuracy for PSP
Mangesius, S., Hussl, A., Krismer, F., Mahlknecht, P., Reiter, E., Tagwercher, S., Djamshidian, A., Schocke, M. F. H., Esterhammer, R., Wenning, G. K., et al. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.10.020 · Cited by 57
Open‐Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy
VandeVrede, L. A., Dale, M. L., Fields, S., Frank, M., Hare, E. B., Heuer, H. W., Keith, K., KOESTLER, M. E., Ljubenkov, P. A., McDermott, D., et al. (2020) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12940 · Cited by 57
Self-citationThe Progressive Supranuclear Palsy Clinical Deficits Scale
Piot, I., Schweyer, K., Respondek, G., Stamelou, M., DescribePSP study group, ProPSP study group, MDS‐endorsed PSP study group, Sckopke, P., Schenk, T., Goetz, C. G., et al. (2020) · Movement Disorders · doi:10.1002/mds.27964 · Cited by 57
Self-citationSNMMI Procedure Standard/EANM Practice Guideline for Brain [ 18 F]FDG PET Imaging, Version 2.0
Arbizu, J., Morbelli, S. D., Minoshima, S., Barthel, H., Kuo, P. H., Weehaeghe, D. V., Horner, N., Colletti, P. M., & Guedj, É. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268754 · Cited by 65
Liu, F., Lu, J., Li, X., Liang, X., Jiao, F., Ge, J., Wu, P., Li, G., Shen, B., Wu, B., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-06104-0 · Cited by 54
Motor, cognitive and behavioral differences in MDS PSP phenotypes
The PSP Salerno study group, Picillo, M., Cuoco, S., Tepedino, M. F., Cappiello, A., Volpe, G., Erro, R., Santangelo, G., Pellecchia, M. T., & Barone, P. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09324-x · Cited by 57
van Eimeren, T., Antonini, A., Berg, D., Bohnen, N. I., Ceravolo, R., Drzezga, A. E., Höglinger, G. U., Higuchi, M., Lehéricy, S., Lewis, S. J. G., et al. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.01.011 · Cited by 53
Self-citationGe, J., Wu, J., Peng, S., Wu, P., Wang, J., Zhang, H., Guan, Y., Eidelberg, D., Zuo, C., & Ma, Y. (2018) · Human Brain Mapping · doi:10.1002/hbm.24044 · Cited by 50
The ProNGF/p75NTR pathway induces tau pathology and is a therapeutic target for FTLD-tau
Shen, L., Manucat-Tan, N. B., Gao, S.-H., Li, W., Zeng, F., Zhu, C., Wang, J., Bu, X., Liu, Y.-H., Gao, C.-Y., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0071-z · Cited by 50
Self-citationFour-Repeat Tauopathies: Current Management and Future Treatments
VandeVrede, L. A., Ljubenkov, P. A., Rojas, J. C., Welch, A. E., & Boxer, A. L. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00888-5 · Cited by 55
Self-citationQuattrone, A., Bianco, M. G., Antonini, A., Vaillancourt, D. E., Seppi, K., Ceravolo, R., Strafella, A. P., Tedeschi, G., Tessitore, A., Cilia, R., et al. (2022) · Movement Disorders · doi:10.1002/mds.28992 · Cited by 49
Tau clearance improves astrocytic function and brain glutamate-glutamine cycle
Hebron, M. L., Javidnia, M., & Moussa, C. (2018) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2018.06.005 · Cited by 50
Alquezar, C., Felix, J. B., McCandlish, E., Buckley, B. T., Caparros-Lefebvre, D., Karch, C. M., Golbe, L. I., & Kao, A. W. (2020) · Scientific Reports · doi:10.1038/s41598-019-56930-w · Cited by 49
Self-citationSaranza, G., Whitwell, J. L., Kovács, G. G., & Lang, A. E. (2019) · International review of neurobiology · doi:10.1016/bs.irn.2019.10.014 · Cited by 52
Self-citationQuattrone, A., Antonini, A., Vaillancourt, D. E., Seppi, K., Ceravolo, R., Strafella, A. P., Morelli, M., Nigro, S. L., Vescio, B., Bianco, M. G., et al. (2020) · Movement Disorders · doi:10.1002/mds.28364 · Cited by 47
Verger, A., Grimaldi, S., Ribeiro, M. J., Frismand, S., & Guedj, É. (2021) · Annals of Neurology · doi:10.1002/ana.26187 · Cited by 47
Frontotemporal dementias: main syndromes and underlying brain changes
Piguet, O., & Kumfor, F. (2020) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000792 · Cited by 49
Richter, D., Bartig, D., Muhlack, S., Hartelt, E., Scherbaum, R., Katsanos, A. H., Müller, T. H., Jost, W. H., Ebersbach, G., Gold, R., et al. (2019) · Cells · doi:10.3390/cells8020151 · Cited by 46
Pyatigorskaya, N., Yahia‐Cherif, L., Gaurav, R., Ewenczyk, C., Galléa, C., Valabrègue, R., Gargouri, F., Magnin, B., Degos, B., Roze, E. F., et al. (2019) · Movement Disorders · doi:10.1002/mds.27877 · Cited by 49
Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy
Song, M., Scheifele, M., Barthel, H., van Eimeren, T., Beyer, L., MAREK, K. L., Eckenweber, F., Palleis, C., Kaiser, L., Finze, A., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05391-3 · Cited by 43
Self-citationIllán‐Gala, I., Nigro, S. L., VandeVrede, L. A., Falgàs, N., Heuer, H. W., Painous, C., Compta, Y., Martí, M. J., Montal, V., Pagonabarraga, J., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.9588 · Cited by 46
Self-citationForrest, S. L., Lee, S., Nassir, N., Martínez-Valbuena, I., Sackmann, V., Li, J., Ahmed, A., Tartaglia, M. C., Ittner, L. M., Lang, A. E., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02604-x · Cited by 44
Self-citationProgressive supranuclear palsy
Giagkou, N., Höglinger, G. U., & Stamelou, M. (2019) · International review of neurobiology · doi:10.1016/bs.irn.2019.10.013 · Cited by 44
Self-citationNeuropathological correlates of structural and functional imaging biomarkers in 4-repeat tauopathies
Spina, S., Brown, J. A., Deng, J., Gardner, R. C., Nana, A. L., Hwang, J.-H. L., Gaus, S. E., Huang, E. J., Kramer, J. H., Rosen, H. J., et al. (2019) · Brain · doi:10.1093/brain/awz122 · Cited by 40
Self-citationNeurodegenerative movement disorders: An epigenetics perspective and promise for the future
Murthy, M. N., Cheng, Y. Y., Holton, J. L., & Bettencourt, C. (2021) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12757 · Cited by 38
İnci, İ., Küsbeci, Ö. Y., & Eşkut, N. (2020) · Neurological Sciences · doi:10.1007/s10072-019-04208-4 · Cited by 40
Quattrone, A., Morelli, M., Quattrone, A., Vescio, B., Nigro, S. L., Arabia, G., Nisticò, R., Novellino, F., Salsone, M., Arcuri, P. P., et al. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.01.019 · Cited by 38
Tauopathy and Movement Disorders—Unveiling the Chameleons and Mimics
Ganguly, J., & Jog, M. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.599384 · Cited by 42
Krzosek, P., Madetko‐Alster, N., Migda, A. M., Migda, B., Jaguś, D., & Alster, P. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.804385 · Cited by 42
Primary retinal tauopathy: A tauopathy with a distinct molecular pattern
Walkiewicz, G., Ronisz, A., Ginderdeuren, R. V., Lemmens, S., Bouwman, F. H., Hoozemans, J. J. M., Morrema, T. H. J., Rozemüller, A. J. M., de Ruyter, F. J. H., Groef, L. D., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13424 · Cited by 34
Sjöström, H., Surova, Y., Nilsson, M., Granberg, T., Westman, E., van Westen, D., Svenningsson, P., & Hansson, O. (2019) · Scientific Reports · doi:10.1038/s41598-019-42565-4 · Cited by 36
Tau PET Imaging with [18F]PM-PBB3 in Frontotemporal Dementia with MAPT Mutation
Su, Y., Fu, J., Yu, J., Zhao, Q., Guan, Y., Zuo, C., Li, M., Tan, H., & Cheng, X. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200287 · Cited by 35
Self-citationClinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants
Street, D., Malpetti, M., Rittman, T., Ghosh, B. C. P., Murley, A. G., Coyle-Gilchrist, I. T. S., Passamonti, L., & Rowe, J. B. (2021) · Brain Communications · doi:10.1093/braincomms/fcab206 · Cited by 37
18F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy
Messerschmidt, K., Barthel, H., Brendel, M., Scherlach, C., Hoffmann, K., Rauchmann, B., Rullmann, M., MAREK, K. L., Villemagne, V. L., Rumpf, J., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262854 · Cited by 35
Self-citationClinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy
Schirinzi, T., Sancesario, G. M., Lazzaro, G. D., Scalise, S., Colona, V. L., Imbriani, P., Mercuri, N. B., Bernardini, S., Lang, A. E., & Pisani, A. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1893-1 · Cited by 36
Self-citationMDS PSP criteria in real‐life clinical setting: Motor and cognitive characterization of subtypes
Picillo, M., Erro, R., Cuoco, S., Tepedino, M. F., Manara, R., Pellecchia, M. T., Barone, P., & for the PSP Salerno Study Group (2018) · Movement Disorders · doi:10.1002/mds.27408 · Cited by 35
Richter, D., Katsanos, A. H., Schroeder, C., Tsivgoulis, G. K., Paraskevas, G. P., Müller, T. H., Alexandrov, A. V., Gold, R., Tönges, L., & Krogias, C. (2019) · Cells · doi:10.3390/cells9010002 · Cited by 35
Tian, H., Wang, J., Feng, R., Zhang, R., Liu, H., Qin, C., Lin, M., Chen, Y., Fu, Y., Liang, D., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101888 · Cited by 34
Martínez-Maldonado, A., Ontiveros‐Torres, M. Á., Harrington, C. R., Montiel-Sosa, J. F., Prandiz, R. G.-T., Bocanegra-López, A. P., Sorsby-Vargas, A. M., Bravo-Muñoz, M., Florán, B., Villanueva‐Fierro, I., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201139 · Cited by 34
Four-Repeat Tau Seeding in the Skin of Patients With Progressive Supranuclear Palsy
Martínez-Valbuena, I., Tartaglia, M. C., Fox, S. H., Lang, A. E., & Kovács, G. G. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.3162 · Cited by 33
Self-citationFalls in Progressive Supranuclear Palsy
Brown, F. S., Rowe, J. B., Passamonti, L., & Rittman, T. (2019) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12879 · Cited by 37
Pharmacological Modulators of Tau Aggregation and Spreading
Dominguez‐Meijide, A., Vasili, E., & Outeiro, T. F. (2020) · Brain Sciences · doi:10.3390/brainsci10110858 · Cited by 36
New insights from a multi-ethnic Asian progressive supranuclear palsy cohort
Lim, S., Closas, A. M. F. D., Tan, A. H., Lim, J. L., Tan, Y. J., Vijayanathan, Y., Tay, Y. W., Khalid, R. B. A., Ng, W. K., Kanesalingam, R., et al. (2023) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2023.105296 · Cited by 32
Peduncolopontine nucleus stimulation in progressive supranuclear palsy: a randomised trial
Scelzo, E., Lozano, A. M., Hamani, C., Poon, Y., AlDakheel, A., Zadikoff, C., Lang, A. E., & Moro, E. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-315192 · Cited by 32
Self-citationHöglinger, G. U. (2017) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12582 · Cited by 35
Self-citationQuattrone, A., Morelli, M., Vescio, B., Nigro, S. L., Piane, E. L., Sabatini, U., Caracciolo, M., Vescio, V., Quattrone, A., Barbagallo, G., et al. (2019) · Movement Disorders · doi:10.1002/mds.27621 · Cited by 32
Therapeutic trial design for frontotemporal dementia and related disorders
Desmarais, P., Rohrer, J. D., Nguyên, Q. D., Herrmann, N., Stuss, D. T., Lang, A. E., Boxer, A. L., Dickerson, B. C., Rosen, H. J., Swieten, J. C. V., et al. (2018) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-318603 · Cited by 35
Self-citation18F-AV1451 PET imaging and multimodal MRI changes in progressive supranuclear palsy
Nicastro, N., Rodríguez, P. V., Malpetti, M., Bevan-Jones, W. R., Jones, P. S., Passamonti, L., Aigbirhio, F. I., O'Brien, J. T., & Rowe, J. B. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09566-9 · Cited by 32
Weber, A., Schwarz, S. C., Tost, J., Trümbach, D., Winter, P., Busato, F., Tacik, P. M., Windhorst, A., Fagny, M., Arzberger, T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05325-y · Cited by 32
Self-citationProgression of two Progressive Supranuclear Palsy phenotypes with comparable initial disability
Shoeibi, A., Litvan, I., TOLOSA, E. S., del Ser, T., & Lee, E. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.07.010 · Cited by 31
Self-citationCognitive and behavioral profile of progressive supranuclear palsy and its phenotypes
Horta‐Barba, A., Pagonabarraga, J., Martínez‐Horta, S., Busteed, L., Pascual‐Sedano, B., Illán‐Gala, I., Marín‐Lahoz, J., Aracil‐Bolaños, I., Pérez‐Pérez, J., Sampedro, F., et al. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10511-y · Cited by 31
Tsujikawa, K., Hamanaka, K., Riku, Y., Hattori, Y., Hara, N., Iguchi, Y., Ishigaki, S., Hashizume, A., Miyatake, S., Mitsuhashi, S., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm5029 · Cited by 33
Tracking brain damage in progressive supranuclear palsy: a longitudinal MRI study
Agosta, F., Caso, F., Ječmenica‐Lukić, M., Petrović, I. N., Valsasina, P., Meani, A., Copetti, M., Kostić, V. S., & Filippi, M. (2018) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-317443 · Cited by 30
Progressive Supranuclear Palsy with Predominant Cerebellar Ataxia
Ando, S., Kanazawa, M., & Onodera, O. (2019) · Journal of Movement Disorders · doi:10.14802/jmd.19061 · Cited by 30
Ng, K. P., Therriault, J., Kang, M. S., Struyfs, H., Pascoal, T. A., Mathotaarachchi, S. S., Shin, M., Benedet, A. L., Massarweh, G., Soucy, J., et al. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.102091 · Cited by 29
Barer, Y., Chodick, G., Cohen, R., Grabarnik‐John, M., Ye, X., Zamudio, J., & Gurevich, T. (2022) · Brain Sciences · doi:10.3390/brainsci12091126 · Cited by 29
Plasma sphingolipid abnormalities in neurodegenerative diseases
Oizumi, H., Sugimura, Y., Totsune, T., Kawasaki, I., Ohshiro, S., Baba, T., Kimpara, T., Sakuma, H., Hasegawa, T., Kawahata, K., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0279315 · Cited by 31
Tau liquid–liquid phase separation: At the crossroads of tau physiology and tauopathy
Islam, M., Shen, F., Regmi, D., Petersen, K., Karim, M. R. U., & Du, D. (2024) · Journal of Cellular Physiology · doi:10.1002/jcp.30853 · Cited by 28
A framework for translating tauopathy therapeutics: Drug discovery to clinical trials
Feldman, H., Cummings, J. L., Boxer, A. L., Staffaroni, A. M., Knopman, D. S., Rizzo, S. J. S., Territo, P. R., Arnold, S. E., Ballard, C. G., Beher, D., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14250 · Cited by 27
Self-citationAzuma, M., Hirai, T., Nakaura, T., Kitajima, M., Yamashita, S., Hashimoto, M., Yamada, K., Uetani, H., Yamashita, Y., & Wang, Y. (2019) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2019.116443 · Cited by 28
Progressive supranuclear palsy, multiple system atrophy and corticobasal degeneration
Fabbrini, G., Fabbrini, A., & Suppa, A. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64012-3.00009-5 · Cited by 29
Metadata
- Authors
- Boxer, A. L., Yu, J.-T., Golbe, L. I., Litvan, I., Lang, A. E., & Höglinger, G. U.
- Affiliations
- University of California, San Francisco (US)
- Qingdao University (CN)
- Rutgers, The State University of New Jersey (US)
- University of California San Diego (US)
- University of Toronto (CA)
- German Center for Neurodegenerative Diseases (DE)
- Corresponding author
- Boxer, Adam L
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 16
- Issue
- 7
- Pages
- 552-563
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC5802400
- OpenAlex
- W2625168757
- Cited by
- 485
- References
- 105
- Citations by year
- 2026: 45 · 2025: 52 · 2024: 59 · 2023: 42 · 2022: 57 · 2021: 56 · 2020: 62 · 2019: 61 · 2018: 43 · 2017: 7
- FWCI
- 6.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- DZNE Pub (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (HO2402/6‐2)
- National Institutes of Health
- National Institute on Aging (P50AG005131, U01AG045390, R01AG038791, P01AG019724)
- National Heart, Lung, and Blood Institute (T35HL007491)
- National Institute of Neurological Disorders and Stroke (U01NS086659, U54NS092089)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- progressive supranuclear palsy, diagnostic criteria, tau pathology, 4-repeat tau, biomarkers, atypical parkinsonism, disease-modifying therapy, neurodegenerative diseases, Alzheimer's disease, chronic traumatic encephalopathy
- MeSH terms
- Humans, Supranuclear Palsy, Progressive, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
